NY-DOUXMATOK
Today, DouxMatok (Israel/USA) and Hi-Food (Italy), two food-tech pioneers leading the development of innovative ingredients, announce a partnership to deliver a complete end-to-end nutritional solution for food manufacturers. DouxMatok’s first-of-its-kind sugar-based sugar reduction solution, Incredo® Sugar , alongside Hi-Food’s semi-solid fiber of natural origin, Meltec® , will allow food brands to address sugar reduction in food products without compromising on taste, texture, sweetness or nutrition.
Incredo Sugar, which officially launched last year and is now commercially available in the U.S., enables up to 50% sugar reduction in food products. The ingredient allows room for nutritional ingredients such as fibers and plant-based proteins, creating a natural fit for a joint effort with Hi-Food’s Meltec, an innovative semi-solid ingredient similar to syrup that is based on vegetable fibers of natural origin. In addition to enriched fiber content, Meltec improves structural properties in food products, is neutral in taste and does not alter odors or colors.
“In partnership with Hi-Food, we’ll be able to deliver more than just a specialty ingredient for great tasting sugar reduction solutions to food brands,” said DouxMatok’s Chief Technology Officer, David Tsivion. “We can provide a full nutritional platform that delivers the scalability and functionality needed for food developers and food production, and the sweetness and mouthfeel that consumers have come to expect.”
The collaborative effort between DouxMatok and Hi-Food addresses one of the most common challenges of existing solutions on the market — maintaining sweetness and other sugar functionalities while avoiding the aftertastes often associated with sugar substitute bulking solutions and addressing other missing sugar functionalities. Research and application development teams at both companies have been working together for over a year to test Incredo® Sugar and Meltec® in combination as pillars to full nutritional solutions in various applications.
“We’re really impressed with the collaborative work of our team and our partners at DouxMatok, and we’re confident in the ability of these combined ingredients to provide a solution that the market is lacking,” said Emanuele Pizzigalli, R&D Officer and co-founder at Hi-Food. “Sugar reduction is a key priority for food manufacturers across the globe, and we’re committed to helping them address this challenge through the use of our fibers with Incredo Sugar.”
The companies have developed product prototypes across a range of applications, including cakes, cookies, chocolate, candy, protein bars, energy bars, snacks, and more. The unique combination of these ingredients also provides an added sustainability value for the food industry as a whole, helping to reduce the environmental impact of overconsumption of sugar, and at the same time exploiting the use of high-quality raw materials from well controlled legumes and cereals supply chains. Products utilizing DouxMatok and Hi-Food’s full nutritional solution are expected to launch in early 2022.
To learn more about DouxMatok and Incredo® Sugar, please visit douxmatok.com or incredosugar.com , or follow along on LinkedIn . For more information about Hi-Food and Meltec® , please visit hifood.it , or follow along on LinkedIn . Organizations interested in working with DouxMatok and Hi-Foods can reach out to partnerships@douxmatok.com and info@hifood.it to learn more about product development opportunities.
About Incredo® Sugar
Recognized as a special mention in the ‘Best Inventions of 2020’ by TIME, Incredo® Sugar is the flagship product of DouxMatok , a global food-tech company pioneering the development of efficient nutrition and flavor technologies and enabling tastier and healthier consumption of foods. Incredo® Sugar is a first-of-its-kind, sugar-based sugar reduction solution that improves the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Based on real cane sugar, this breakthrough, patented sugar reduction solution enables food manufacturers to develop delicious, better-for-you formulations that deliver great taste experiences and enhance nutritional values of sweet food products while reducing sugar. In April 2021, DouxMatok launched its first product, limited edition Incredo Spreads in two flavors via shop.incredosugar.com . For more information, please visit incredosugar.com , or follow along on Facebook and Instagram .
About DouxMatok
DouxMatok is pioneering the development of efficient nutrition and flavor delivery technologies of food products. Patented through 24 granted patents, its sugar reduction solution, Incredo® Sugar, maximizes the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness, enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Independent consumer and expert sensory panel tests have confirmed that, when using Incredo® Sugar, it is possible to reduce 30%-50% of the sugar levels in a wide range of food and snack products while retaining consumer preferences. For more information, please visit douxmatok.com , or follow along on LinkedIn .
About Meltec®
Meltec® – award winning and patented – semi-solid innovative ingredient is rich in fiber and guarantees excellent texturing and bulking properties without sweetening. Produced in Italy, this ingredient made by ingredients of natural origin (corn and chickpeas) is neutral in taste and smell and has less than 1% of sugars. Apparently similar to honey or glucose syrup, Meltec® is suitable for all sugar-free / low-sugar applications, acts as a humectant, texturizing, thickening, filling, cryoprotectant agent and reducing freezing point in a wide range of foods: typical applications include bars, granolas, cakes, ice-creams, sauces and fillings. For more information, please visit hifood.it .
About Hi-Food
Hi-Food was founded in 2012 in Parma, at the heart of Italy’s “Food Valley,” by a group of entrepreneurs with a proven track record in the natural ingredients sector. Over the years, the Company has developed deep expertise and applications knowledge in producing and using natural products, such as new fibers, proteins, gluten-free nucleus, clean label and plant-based systems to create customized functional solutions for conventional and disruptive food industry (traditional bakery, gluten free, gastronomy, sauces, fillings, dessert, ice cream, beverage, new plant-based foods). The R&D team are on-hand to answer questions and solve issues about shelf-life, stability, sugar/salt/fat reduction, egg replacement, fiber/protein enrichment, structure improvement or many other needs which are suitable for its ingredients, and customer finished product. Hi-Food operates research and production facilities in Italy and is expanding its footprint with a state-of-the-art new production plant and R&D application center in Parma. For more information, please visit hifood.it or follow along on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005022/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom